GSK Pharma Q4 FY25 Results: Net Profit at ₹260 Crore, ₹42 Dividend Declared

23 4

GlaxoSmithKline Pharmaceuticals Ltd (GSK Pharma) has reported a net profit of ₹260 crore for Q4 FY25, marking a 32% year-on-year increase, driven by strong growth in its General Medicines, Specialty, and Vaccines portfolio.

Revenue Growth and Profitability

The company’s revenue rose 6% YoY to ₹966 crore, while full-year revenue stood at ₹3,723 crore, reflecting a 9% annual growth.

GSK Pharma’s EBITDA margins expanded by 500 basis points to 31.4%, supported by cost efficiencies and improved productivity.

Dividend Announcement

The Board of Directors has recommended a final dividend of ₹42 per equity share, subject to approval at the 100th Annual General Meeting. The record date for the dividend is May 30, 2025.

Strategic Expansion and Future Outlook

GSK Pharma is set to launch two oncology assets in IndiaZejula (Niraparib), a PARP inhibitor for ovarian cancer, and Jemperli (Dostarlimab), an immunotherapy for endometrial cancer.

Managing Director Bhushan Akshikar emphasized that digital acceleration and enhanced healthcare professional engagement have strengthened GSK’s market presence and customer reach.

Stock Performance and Market Sentiment

Following the earnings announcement, GSK Pharma’s shares surged 3.22%, closing at ₹2,809 per share, reflecting strong investor confidence.

With continued innovation and strategic expansion, GSK Pharma remains well-positioned for sustained growth in India’s pharmaceutical sector.

Leave a Reply

Your email address will not be published. Required fields are marked *